Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | PTAFR | P25105 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13200940 | 1.00 | TACR1 (0.58) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL2802424 | 0.92 | TACR1 (0.47) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13200935 | 0.92 | TACR1 (0.47) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13201200 | 0.89 | TACR1 (0.59) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL2802415 | 0.89 | TACR1 (0.59) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13200543 | 0.89 | TACR1 (0.56) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13200944 | 0.87 | TACR1 (0.56) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13200969 | 0.87 | TACR1 (0.54) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13196716 | 0.85 | TACR1 (0.65) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL13200549 | 0.85 | TACR1 (0.65) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | BAO JIANMING | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197724-A1 | 6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | TACR1, TACR2, HTR1D | TACR1 1/4885SIGMAR1 698/4885PTAFR 1030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.